The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. Galapagos disavows any obligation to update the information contained in such press releases after the date of their issuance.
25 July
Strong clinical progress in H1 and transformative collaboration with Gilead announced
18 July
14 July
GILEAD AND GALAPAGOS ENTER INTO TRANSFORMATIVE RESEARCH AND DEVELOPMENT COLLABORATION
02 July
20 June
Galapagos increases share capital through warrant exercises
17 June
11 June
29 May
25 April
Galapagos reports on historic first quarter 2019
23 April
10 April
Galapagos creates new warrant plans
29 March
Publication of the annual report and invitation to the annual shareholders' meeting
28 March
GILEAD AND GALAPAGOS REPORT UPDATED SAFETY INFORMATION FOR FILGOTINIB IN RHEUMATOID ARTHRITIS (RA)
28 March
28 March
20 March
Galapagos increases share capital through warrant exercises
21 February
Firmly on our way to becoming a fully integrated biopharma company
07 February
Evotec and Galapagos enter into collaboration in the field of fibrosis
08 January
Sands Capital reports 5.7% holding in Galapagos
07 January
Galapagos starts first Phase 1 trial with Toledo compound
06 January
Galapagos initiates NOVESA Phase 2a trial in patients with systemic sclerosis
04 January
11 June
29 May
07 February
Evotec and Galapagos enter into collaboration in the field of fibrosis
07 January
Galapagos starts first Phase 1 trial with Toledo compound
06 January
Galapagos initiates NOVESA Phase 2a trial in patients with systemic sclerosis
04 January
25 July
Strong clinical progress in H1 and transformative collaboration with Gilead announced
18 July
14 July
GILEAD AND GALAPAGOS ENTER INTO TRANSFORMATIVE RESEARCH AND DEVELOPMENT COLLABORATION
02 July
20 June
Galapagos increases share capital through warrant exercises
17 June
25 April
Galapagos reports on historic first quarter 2019
23 April
10 April
Galapagos creates new warrant plans
29 March
Publication of the annual report and invitation to the annual shareholders' meeting
28 March
GILEAD AND GALAPAGOS REPORT UPDATED SAFETY INFORMATION FOR FILGOTINIB IN RHEUMATOID ARTHRITIS (RA)
28 March
28 March
20 March
Galapagos increases share capital through warrant exercises
21 February
Firmly on our way to becoming a fully integrated biopharma company
08 January
21 December
Galapagos to Present at 37th Annual J.P. Morgan Healthcare Conference
17 December
27 November
Galapagos receives Fast Track designation from FDA for GLPG1972/S201086 in osteoarthritis
26 November
23 November
Galapagos increases share capital through warrant exercises
31 October
24 October
Hallmark third quarter 2018 and Annual R&D Update at Galapagos
24 October
Galapagos and AbbVie restructure CF collaboration
24 October
Topline interim results of FALCON trial Part 1 in CF
22 October
21 October
03 October
Galapagos increases share capital through warrant exercises
24 September
17 September
Galapagos issues new shares as result of public offering
17 September
13 September
Galapagos and MorphoSys announce start of a Phase 1 subcutaneous bridging study with MOR106
13 September
Galapagos raises $300 million gross proceeds in a U.S. public offering
12 September
Galapagos announces launch of proposed public offering
12 September
11 September
06 September
02 August
Productive first half-year at Galapagos
19 July
MorphoSys and Galapagos Sign Global License Agreement for MOR106 with Top Pharma Partner
09 July
Galapagos announces design for PINTA Phase 2 trial with GLPG1205 in IPF
28 June
Topline results of PELICAN trial and update on triple combo development plans
26 June
20 June
Galapagos increases share capital through warrant exercises
14 June
30 May
20 May
GLPG1690 results in IPF published in The Lancet Respiratory Medicine and presented at ATS
01 May
27 April
25 April
Galapagos reports first quarter 2018 results
24 April
Galapagos reports initiation of FALCON clinical trial in cystic fibrosis
19 April
Galapagos creates new warrant plan
12 April
Galapagos announces ISABELA Phase 3 program in IPF
23 March
Publication of the annual report and invitation to the annual shareholders' meeting
20 March
Galapagos increases share capital through warrant exercises
22 February
17 February
07 January
Positive topline results with GLPG1972 in osteoarthritis patients
02 January
21 December
Galapagos to Present at 37th Annual J.P. Morgan Healthcare Conference
17 December
27 November
Galapagos receives Fast Track designation from FDA for GLPG1972/S201086 in osteoarthritis
31 October
24 October
Hallmark third quarter 2018 and Annual R&D Update at Galapagos
22 October
21 October
24 September
13 September
Galapagos and MorphoSys announce start of a Phase 1 subcutaneous bridging study with MOR106
12 September
09 July
Galapagos announces design for PINTA Phase 2 trial with GLPG1205 in IPF
26 June
20 May
GLPG1690 results in IPF published in The Lancet Respiratory Medicine and presented at ATS
01 May
24 April
Galapagos reports initiation of FALCON clinical trial in cystic fibrosis
12 April
Galapagos announces ISABELA Phase 3 program in IPF
17 February
07 January
Positive topline results with GLPG1972 in osteoarthritis patients
02 January
26 November
23 November
Galapagos increases share capital through warrant exercises
24 October
Galapagos and AbbVie restructure CF collaboration
24 October
Topline interim results of FALCON trial Part 1 in CF
03 October
Galapagos increases share capital through warrant exercises
17 September
Galapagos issues new shares as result of public offering
17 September
13 September
Galapagos raises $300 million gross proceeds in a U.S. public offering
12 September
Galapagos announces launch of proposed public offering
11 September
06 September
02 August
Productive first half-year at Galapagos
19 July
MorphoSys and Galapagos Sign Global License Agreement for MOR106 with Top Pharma Partner
28 June
Topline results of PELICAN trial and update on triple combo development plans
20 June
Galapagos increases share capital through warrant exercises
14 June
30 May
27 April
25 April
Galapagos reports first quarter 2018 results
19 April
Galapagos creates new warrant plan
23 March
Publication of the annual report and invitation to the annual shareholders' meeting
20 March
Galapagos increases share capital through warrant exercises
22 February
18 December
14 December
11 December
11 December
Galapagos to enter NASDAQ Biotech Index
23 November
Galapagos increases share capital through warrant exercises
21 November
Galapagos initiates Phase 1 study with novel CF corrector GLPG3221
19 November
ALBATROSS with GLPG2222 shows positive clinical results in CF patients
05 November
02 November
Galapagos moving forward in CF programs at NACFC 2017
26 October
Galapagos Q3: clinical success with GLPG1690 and MOR106 highlights strength of deep pipeline
27 September
21 September
Galapagos increases share capital through warrant exercises
09 August
GLPG1690 halts disease progression in IPF patients in FLORA Phase 2a trial
27 July
Solid financials support R&D progress
27 July
Servier licenses GLPG1972 in osteoarthritis from Galapagos
05 July
New Phase 2 study with filgotinib in non-infectious uveitis
20 June
Galapagos increases share capital through warrant exercises
20 June
Galapagos' R&D Update 2017: rapidly advancing our product candidates
17 May
Galapagos creates new warrant plan
17 May
Galapagos to hold Annual R&D Update 2017 on 20 June
15 May
Seven abstracts on filgotinib accepted by EULAR 2017
07 May
Galapagos presents three posters on filgotinib in Crohn's disease at DDW® 2017
29 April
27 April
Galapagos reports first quarter 2017 results
25 April
21 April
Galapagos announces capital increase
21 April
18 April
Galapagos raises $338 million gross proceeds in a U.S. public offering
17 April
Galapagos announces launch of proposed public offering
06 April
Galapagos increases share capital through warrant exercises
05 April
Galapagos doses first psoriatic arthritis patient with filgotinib
04 April
Galapagos announces three new Phase 2 Proof-of-Concept studies with filgotinib
23 March
22 March
Galapagos initiates Phase 1 study with novel CF potentiator GLPG3067
10 March
New Phase 2 studies with filgotinib in small bowel and fistulizing Crohn's disease
23 February
Galapagos doses first healthy volunteer with CF combo GLPG2222 and GLPG2451
23 February
Galapagos reports strong financial results and newsflow-rich pipeline
01 February
Galapagos doses first patient with novel CF corrector GLPG2222
20 January
Galapagos creates new warrant plan
17 January
14 December
11 December
Galapagos to enter NASDAQ Biotech Index
21 November
Galapagos initiates Phase 1 study with novel CF corrector GLPG3221
19 November
ALBATROSS with GLPG2222 shows positive clinical results in CF patients
05 November
02 November
Galapagos moving forward in CF programs at NACFC 2017
27 September
05 July
New Phase 2 study with filgotinib in non-infectious uveitis
17 May
Galapagos to hold Annual R&D Update 2017 on 20 June
15 May
Seven abstracts on filgotinib accepted by EULAR 2017
07 May
Galapagos presents three posters on filgotinib in Crohn's disease at DDW® 2017
29 April
25 April
06 April
Galapagos increases share capital through warrant exercises
05 April
Galapagos doses first psoriatic arthritis patient with filgotinib
04 April
Galapagos announces three new Phase 2 Proof-of-Concept studies with filgotinib
10 March
New Phase 2 studies with filgotinib in small bowel and fistulizing Crohn's disease
23 February
Galapagos doses first healthy volunteer with CF combo GLPG2222 and GLPG2451
17 January
18 December
11 December
23 November
Galapagos increases share capital through warrant exercises
26 October
Galapagos Q3: clinical success with GLPG1690 and MOR106 highlights strength of deep pipeline
21 September
Galapagos increases share capital through warrant exercises
09 August
GLPG1690 halts disease progression in IPF patients in FLORA Phase 2a trial
27 July
Solid financials support R&D progress
27 July
Servier licenses GLPG1972 in osteoarthritis from Galapagos
20 June
Galapagos increases share capital through warrant exercises
20 June
Galapagos' R&D Update 2017: rapidly advancing our product candidates
17 May
Galapagos creates new warrant plan
27 April
Galapagos reports first quarter 2017 results
21 April
Galapagos announces capital increase
21 April
18 April
Galapagos raises $338 million gross proceeds in a U.S. public offering
17 April
Galapagos announces launch of proposed public offering
23 March
22 March
Galapagos initiates Phase 1 study with novel CF potentiator GLPG3067
23 February
Galapagos reports strong financial results and newsflow-rich pipeline
01 February
Galapagos doses first patient with novel CF corrector GLPG2222
20 January
20 December
SAPHIRA 1 topline shows competitive clinical results in G551D patients
15 December
The Lancet publishes FITZROY study results with filgotinib in Crohn's disease
08 December
Start Phase 2b/3 study with filgotinib in ulcerative colitis
29 November
Galapagos increases share capital through warrant exercises
28 November
Galapagos initiates Phase 1 study with cystic fibrosis drug GLPG2737
24 November
Galapagos selected for Stoxx Europe 600 Index
22 November
Phase 3 study with filgotinib initiated in Crohn's disease
27 October
27 October
Galapagos to present progress in CF programs at NACFC 2016
12 October
Transparency notification - FMR LLC reaches 10% threshold
11 October
Invitation to Galapagos investor relations program @ NACFC 2016
29 September
MorphoSys and Galapagos Start First-In-Patient Dosing of IL-17C Antibody MOR106 in Atopic Dermatitis
27 September
26 September
19 September
Galapagos increases share capital through warrant exercises
06 September
Orphan Drug Designation in European Union for GLPG1690 in idiopathic pulmonary fibrosis
22 August
FINCH filgotinib Phase 3 program initiated in rheumatoid arthritis
29 July
Galapagos receives transparency notification from Federated
28 July
Focus on filgotinib and cystic fibrosis
23 June
15 June
09 June
Galapagos selected for AEX Index
01 June
Galapagos creates new warrant plan
25 May
FITZROY Phase 2 study with filgotinib in Crohn's Disease presented as late breaker at DDW 2016
24 May
Successful completion of End-of-Phase 2 FDA and EMA consultations in rheumatoid arthritis (RA)
19 May
Galapagos increases share capital through warrant exercises
17 May
Listing of existing shares on Euronext Brussels & Amsterdam
09 May
Galapagos starts Phase 1 study with potentiator GLPG2451 for CF
29 April
Galapagos and AbbVie expand their cystic fibrosis collaboration
28 April
Galapagos kick-starts 2016 with Q1 cash position of €988 M
21 April
Galapagos reports additional data with filgotinib from the Phase 2 FITZROY study
07 April
Galapagos and MorphoSys initiate Phase 1 study in joint antibody program MOR106
06 April
Galapagos initiates a Phase 2a study with GLPG1690 in idiopathic pulmonary fibrosis patients
01 April
Galapagos increases share capital through warrant exercises
25 March
18 March
Results from 10-week analysis of Phase 2 study with filgotinib in Crohn's Disease presented at ECCO
16 March
Galapagos doses first CF patient with G551D mutation in SAPHIRA 1 study
07 March
Galapagos selected for BEL 20 Index
03 March
Galapagos reports largest cash balance ever
01 March
Galapagos receives transparency notification from Johnson & Johnson
16 February
Galapagos starts SAPHIRA Phase 2 study with GLPG1837 in cystic fibrosis patients
01 February
Galapagos receives transparency notification from Wellington Management Group LLP
26 January
Galapagos reports results with GLPG1205 in ulcerative colitis
25 January
Transparency notification - Gilead Sciences, Inc. holds 14.75% of Galapagos shares
19 January
Galapagos and Gilead complete closing of their global collaboration for filgotinib
19 January
Galapagos advances CF clinical development
13 January
Galapagos and Gilead cleared by US FTC to close their global partnership on filgotinib
15 December
The Lancet publishes FITZROY study results with filgotinib in Crohn's disease
24 November
Galapagos selected for Stoxx Europe 600 Index
27 October
Galapagos to present progress in CF programs at NACFC 2016
11 October
Invitation to Galapagos investor relations program @ NACFC 2016
29 September
MorphoSys and Galapagos Start First-In-Patient Dosing of IL-17C Antibody MOR106 in Atopic Dermatitis
06 September
Orphan Drug Designation in European Union for GLPG1690 in idiopathic pulmonary fibrosis
22 August
FINCH filgotinib Phase 3 program initiated in rheumatoid arthritis
09 June
Galapagos selected for AEX Index
25 May
FITZROY Phase 2 study with filgotinib in Crohn's Disease presented as late breaker at DDW 2016
18 March
Results from 10-week analysis of Phase 2 study with filgotinib in Crohn's Disease presented at ECCO
07 March
20 December
SAPHIRA 1 topline shows competitive clinical results in G551D patients
08 December
Start Phase 2b/3 study with filgotinib in ulcerative colitis
29 November
Galapagos increases share capital through warrant exercises
28 November
Galapagos initiates Phase 1 study with cystic fibrosis drug GLPG2737
22 November
Phase 3 study with filgotinib initiated in Crohn's disease
27 October
12 October
Transparency notification - FMR LLC reaches 10% threshold
27 September
26 September
19 September
Galapagos increases share capital through warrant exercises
29 July
Galapagos receives transparency notification from Federated
28 July
Focus on filgotinib and cystic fibrosis
23 June
15 June
01 June
Galapagos creates new warrant plan
24 May
Successful completion of End-of-Phase 2 FDA and EMA consultations in rheumatoid arthritis (RA)
19 May
Galapagos increases share capital through warrant exercises
17 May
Listing of existing shares on Euronext Brussels & Amsterdam
09 May
Galapagos starts Phase 1 study with potentiator GLPG2451 for CF
29 April
Galapagos and AbbVie expand their cystic fibrosis collaboration
28 April
Galapagos kick-starts 2016 with Q1 cash position of €988 M
21 April
Galapagos reports additional data with filgotinib from the Phase 2 FITZROY study
07 April
Galapagos and MorphoSys initiate Phase 1 study in joint antibody program MOR106
06 April
Galapagos initiates a Phase 2a study with GLPG1690 in idiopathic pulmonary fibrosis patients
01 April
Galapagos increases share capital through warrant exercises
25 March
16 March
Galapagos doses first CF patient with G551D mutation in SAPHIRA 1 study
03 March
Galapagos reports largest cash balance ever
01 March
Galapagos receives transparency notification from Johnson & Johnson
16 February
Galapagos starts SAPHIRA Phase 2 study with GLPG1837 in cystic fibrosis patients
01 February
Galapagos receives transparency notification from Wellington Management Group LLP
26 January
Galapagos reports results with GLPG1205 in ulcerative colitis
25 January
Transparency notification - Gilead Sciences, Inc. holds 14.75% of Galapagos shares
19 January
Galapagos and Gilead complete closing of their global collaboration for filgotinib
19 January
Galapagos advances CF clinical development
13 January
Galapagos and Gilead cleared by US FTC to close their global partnership on filgotinib
22 December
Galapagos creates new warrant plans
22 December
Galapagos receives transparency notification from Wellington Management Group LLP
17 December
07 December
04 December
Galapagos increases share capital through warrant exercises
20 November
Invitation to the Special Shareholders' Meeting of Galapagos on 22 December 2015
20 November
12 November
Galapagos reports third quarter 2015 cash position of €374 M
08 November
Galapagos builds on strong profile of filgotinib in 7 presentations at ACR 2015
04 November
Dr. Christine Mummery appointed to Galapagos' Board of Directors
15 October
Galapagos advances triple combination therapy in cystic fibrosis
09 October
Positive safety and tolerability for novel potentiator GLPG1837
08 October
Galapagos to present promising findings in cystic fibrosis programs at NACFC 2015
02 October
Galapagos raises €1.2 million through warrant exercises
25 September
Galapagos to advance filgotinib to Phase 3 in rheumatoid arthritis
22 September
10 August
06 August
Patient recruitment completed in FITZROY Phase 2 Crohn's disease study with filgotinib
05 August
Galapagos on track to deliver on pipeline in second half 2015
29 July
15 July
19 June
Galapagos raises €4.4 million through warrant exercises
18 June
15 June
10 June
Galapagos DARWIN 1 and 2 studies have completed 24 weeks of treatment
26 May
Galapagos receives transparency notifications
19 May
Galapagos announces capital increase
19 May
Galapagos announces closing of NASDAQ IPO
18 May
Galapagos announces full exercise of underwriters' option to purchase additional shares
14 May
Galapagos raises $275 million gross proceeds with NASDAQ IPO
12 May
Galapagos announces size of global offering increased to $250 million
07 May
06 May
Galapagos announces launch of proposed global offering
06 May
Galapagos listed 10 years on Euronext Amsterdam and Brussels
01 May
BNP Paribas notify of 4.8% shareholding in Galapagos
01 May
Galapagos creates new warrant plan
27 April
Filgotinib as monotherapy also hits primary endpoint in DARWIN 2 trial
15 April
Galapagos files registration statement in the United States for a proposed global offering
14 April
27 March
27 March
17 March
Galapagos regains rights to GLPG1690, announces end of alliance with Janssen
06 March
Galapagos to be included in Amsterdam Midcap Index
06 March
Galapagos reports 2014 financial results
23 February
Galapagos reports that the last patient in DARWIN 1 has completed 12 weeks of treatment
16 February
Galapagos reports positive Phase 1 results for GLPG1690
11 February
Galapagos receives €1.6 million IWT grant for hepatitis B program
09 February
BNP Paribas notify of 5.08% shareholding in Galapagos
22 January
Galapagos receives €2.5 million IWT grant for antibiotic research
21 January
Delta Lloyd notify of 4.96% shareholding in Galapagos
09 January
Vicki Sato resigns from Galapagos Board
08 January
Galapagos starts Phase 2 trial with GLPG1205 in ulcerative colitis patients
08 November
Galapagos builds on strong profile of filgotinib in 7 presentations at ACR 2015
04 November
Dr. Christine Mummery appointed to Galapagos' Board of Directors
22 September
15 July
06 May
Galapagos listed 10 years on Euronext Amsterdam and Brussels
06 March
Galapagos to be included in Amsterdam Midcap Index
23 February
Galapagos reports that the last patient in DARWIN 1 has completed 12 weeks of treatment
11 February
Galapagos receives €1.6 million IWT grant for hepatitis B program
22 January
Galapagos receives €2.5 million IWT grant for antibiotic research
09 January
Vicki Sato resigns from Galapagos Board
08 January
Galapagos starts Phase 2 trial with GLPG1205 in ulcerative colitis patients
22 December
Galapagos creates new warrant plans
22 December
Galapagos receives transparency notification from Wellington Management Group LLP
17 December
07 December
04 December
Galapagos increases share capital through warrant exercises
20 November
Invitation to the Special Shareholders' Meeting of Galapagos on 22 December 2015
20 November
12 November
Galapagos reports third quarter 2015 cash position of €374 M
15 October
Galapagos advances triple combination therapy in cystic fibrosis
09 October
Positive safety and tolerability for novel potentiator GLPG1837
08 October
Galapagos to present promising findings in cystic fibrosis programs at NACFC 2015
02 October
Galapagos raises €1.2 million through warrant exercises
25 September
Galapagos to advance filgotinib to Phase 3 in rheumatoid arthritis
10 August
06 August
Patient recruitment completed in FITZROY Phase 2 Crohn's disease study with filgotinib
05 August
Galapagos on track to deliver on pipeline in second half 2015
29 July
19 June
Galapagos raises €4.4 million through warrant exercises
18 June
15 June
10 June
Galapagos DARWIN 1 and 2 studies have completed 24 weeks of treatment
26 May
Galapagos receives transparency notifications
19 May
Galapagos announces capital increase
19 May
Galapagos announces closing of NASDAQ IPO
18 May
Galapagos announces full exercise of underwriters' option to purchase additional shares
14 May
Galapagos raises $275 million gross proceeds with NASDAQ IPO
12 May
Galapagos announces size of global offering increased to $250 million
07 May
06 May
Galapagos announces launch of proposed global offering
01 May
BNP Paribas notify of 4.8% shareholding in Galapagos
01 May
Galapagos creates new warrant plan
27 April
Filgotinib as monotherapy also hits primary endpoint in DARWIN 2 trial
15 April
Galapagos files registration statement in the United States for a proposed global offering
14 April
27 March
27 March
17 March
Galapagos regains rights to GLPG1690, announces end of alliance with Janssen
06 March
Galapagos reports 2014 financial results
16 February
Galapagos reports positive Phase 1 results for GLPG1690
09 February
BNP Paribas notify of 5.08% shareholding in Galapagos
21 January
19 December
16 December
Galapagos regains full rights to GPR84 inhibitor GLPG1205
12 December
Galapagos selects second component of its investigational cystic fibrosis combination treatment
09 December
Galapagos increases share capital through warrant exercises
24 November
Galapagos completes recruitment for Darwin 2 monotherapy study with GLPG0634 (filgotinib) in RA
17 November
Galapagos presents clean drug-drug interaction profile with GLPG0634 (filgotinib) at ACR 2014
12 November
Galapagos completes recruitment for Darwin 1 study with GLPG0634 (filgotinib) in RA
06 November
GSK discloses good efficacy in psoriasis with GSK2856184
27 October
20 October
Galapagos discloses novel target and presents favorable Phase 1 data for GLPG1205 at UEG Week
17 October
Galapagos creates new warrant plan
15 October
Bart Filius joins Galapagos as CFO
09 October
Galapagos presents novel cystic fibrosis combination therapy at NACFC
25 September
Galapagos increases share capital through warrant exercises
18 September
Galapagos reports high participation rate in long term extension study with GLPG0634 in RA patients
08 August
Galapagos cash position of €232 M provides solid basis for R&D pipeline investment
05 August
Galapagos receives milestone in osteoarthritis alliance with Servier
25 July
Galapagos creates new warrant plan
23 July
04 July
Galapagos raises €1.9 million through warrant exercises
01 July
17 June
Galapagos cystic fibrosis program progresses towards therapy for largest patient group
12 May
Galapagos to hold Annual R&D Update on 17 June 2014 in New York
30 April
Invitation to the Extraordinary General Shareholders' Meeting to be held on 19 May 2014
28 April
Galapagos announces management change
24 April
Baker Brothers notify of 4.99% shareholding in Galapagos
17 April
GSK2586184 met primary endpoint in Phase 2a psoriasis study
10 April
Galapagos raises €2.4 million through warrant exercises
01 April
Charles River Laboratories and Galapagos complete transaction
28 March
21 March
Euronext Amsterdam to become Market of Reference for Galapagos
18 March
13 March
07 March
Galapagos reports 2013 financial results
07 March
Galapagos receives €2 million from osteoarthritis alliance with Servier
28 February
21 February
Galapagos to present GLPG0634 and GLPG0974 at International Conference on IBD
17 February
03 February
Galapagos receives €2.3 million IWT grant for fibrosis research
29 January
First clinical centers opened for Phase 2 Crohn's study with GLPG0634
13 January
Galapagos receives €2.9 million IWT grant for cystic fibrosis research
06 January
Van Herk Investments notify of 5.3% shareholding in Galapagos
19 December
16 December
12 December
Galapagos selects second component of its investigational cystic fibrosis combination treatment
09 December
Galapagos increases share capital through warrant exercises
24 November
Galapagos completes recruitment for Darwin 2 monotherapy study with GLPG0634 (filgotinib) in RA
17 November
Galapagos presents clean drug-drug interaction profile with GLPG0634 (filgotinib) at ACR 2014
12 November
Galapagos completes recruitment for Darwin 1 study with GLPG0634 (filgotinib) in RA
06 November
GSK discloses good efficacy in psoriasis with GSK2856184
27 October
20 October
Galapagos discloses novel target and presents favorable Phase 1 data for GLPG1205 at UEG Week
17 October
Galapagos creates new warrant plan
15 October
Bart Filius joins Galapagos as CFO
09 October
Galapagos presents novel cystic fibrosis combination therapy at NACFC
25 September
Galapagos increases share capital through warrant exercises
18 September
Galapagos reports high participation rate in long term extension study with GLPG0634 in RA patients
08 August
Galapagos cash position of €232 M provides solid basis for R&D pipeline investment
05 August
Galapagos receives milestone in osteoarthritis alliance with Servier
25 July
Galapagos creates new warrant plan
23 July
04 July
Galapagos raises €1.9 million through warrant exercises
01 July
17 June
Galapagos cystic fibrosis program progresses towards therapy for largest patient group
12 May
Galapagos to hold Annual R&D Update on 17 June 2014 in New York
30 April
Invitation to the Extraordinary General Shareholders' Meeting to be held on 19 May 2014
28 April
Galapagos announces management change
24 April
Baker Brothers notify of 4.99% shareholding in Galapagos
17 April
GSK2586184 met primary endpoint in Phase 2a psoriasis study
10 April
Galapagos raises €2.4 million through warrant exercises
01 April
Charles River Laboratories and Galapagos complete transaction
28 March
21 March
Euronext Amsterdam to become Market of Reference for Galapagos
18 March
13 March
07 March
Galapagos reports 2013 financial results
07 March
Galapagos receives €2 million from osteoarthritis alliance with Servier
28 February
21 February
Galapagos to present GLPG0634 and GLPG0974 at International Conference on IBD
17 February
03 February
Galapagos receives €2.3 million IWT grant for fibrosis research
29 January
First clinical centers opened for Phase 2 Crohn's study with GLPG0634
13 January
Galapagos receives €2.9 million IWT grant for cystic fibrosis research
06 January
Van Herk Investments notify of 5.3% shareholding in Galapagos
16 December
Galapagos selects pre-clinical candidate for cystic fibrosis
06 December
Galapagos increases share capital through warrant exercises
04 December
Galapagos reports positive Phase 1 results for GLPG1205
27 November
Galapagos announces GSK2586184 JAK1 molecule moves into Phase 2 for ulcerative colitis
20 November
15 November
12 November
Galapagos subsidiary BioFocus signs agreement with Biogen Idec in scleroderma
21 October
Galapagos increases share capital through warrant exercises
17 October
Galapagos presents superior potentiator series for CF
16 October
Galapagos to present GLPG0634 at ACR
16 October
Galapagos to present Phase 1 data on FFA2 antagonist GLPG0974 at UEG Week in Berlin
30 September
Delta Lloyd notify of 9.93% shareholding in Galapagos
24 September
AbbVie and Galapagos to co-develop cystic fibrosis therapies
18 September
Galapagos creates new warrant plan
20 August
Galapagos appoints David Smith as CEO of Service Division
09 August
Galapagos half year revenues up 21%
23 July
Galapagos delivers novel osteoarthritis molecules in alliance with Servier
08 July
Galapagos receives €2.4 million IWT grant for psoriasis research
02 July
Galapagos initiates Phase 1 trial as part of its alliance with Janssen Pharmaceutica NV
01 July
Galapagos increases share capital through warrant exercises
01 July
First patients screened for Phase 2B studies with GLPG0634
13 June
Galapagos presents GLPG0634 at EULAR poster session
17 May
Galapagos creates new warrant plan
17 May
17 May
AbbVie and Galapagos extend GLPG0634 collaboration to include Crohn's disease
13 May
Galapagos to present three posters on GLPG0634 at EULAR
30 April
NYSE Liffe lists Equity Options on Galapagos
29 April
Galapagos completes private placement by issuance of 2,696,831 new ordinary shares
25 April
24 April
Galapagos to raise capital via a private placement of new shares
23 April
Galapagos starts Phase 2A study with GLPG0974 in ulcerative colitis
22 April
Galapagos discovers novel candidate drug to treat breast cancer
16 April
Galapagos presents scope of GLPG0634 Phase 2b program
12 April
Gestion notify of 4.97% shareholding in Galapagos
08 April
Galapagos increases share capital through warrant exercises
27 March
Galapagos to start Phase 2a study with GLPG0974 in IBD patients
27 March
20 March
Galapagos to host annual R&D update on 27 March
08 March
Galapagos reports record revenues in 2012, increasing momentum in clinical pipeline
08 March
Galapagos and Roche conclude strategic alliance
06 March
Galapagos receives €7.5 million in Servier alliances
04 March
Katrine Bosley appointed to Galapagos' Board of Directors
05 February
Galapagos announces GSK2586184 JAK1 molecule progresses to Phase 2 studies
30 January
Galapagos receives €2.5 million IWT grant for IBD research
16 January
15 January
Galapagos creates Fidelta, a third Galapagos service division
15 January
Galapagos acquires Cangenix, a structure-based drug discovery company
10 January
Galapagos receives €2.7 million IWT grant for antibacterial research
09 January
Galapagos delivers candidate drug in GSK alliance and receives milestone payment
06 January
Galapagos to present at the 31st annual J. P. Morgan Healthcare Conference
16 December
Galapagos selects pre-clinical candidate for cystic fibrosis
06 December
Galapagos increases share capital through warrant exercises
04 December
Galapagos reports positive Phase 1 results for GLPG1205
27 November
Galapagos announces GSK2586184 JAK1 molecule moves into Phase 2 for ulcerative colitis
20 November
15 November
12 November
Galapagos subsidiary BioFocus signs agreement with Biogen Idec in scleroderma
21 October
Galapagos increases share capital through warrant exercises
17 October
Galapagos presents superior potentiator series for CF
16 October
Galapagos to present GLPG0634 at ACR
16 October
Galapagos to present Phase 1 data on FFA2 antagonist GLPG0974 at UEG Week in Berlin
30 September
Delta Lloyd notify of 9.93% shareholding in Galapagos
24 September
AbbVie and Galapagos to co-develop cystic fibrosis therapies
18 September
Galapagos creates new warrant plan
20 August
Galapagos appoints David Smith as CEO of Service Division
09 August
Galapagos half year revenues up 21%
23 July
Galapagos delivers novel osteoarthritis molecules in alliance with Servier
08 July
Galapagos receives €2.4 million IWT grant for psoriasis research
02 July
Galapagos initiates Phase 1 trial as part of its alliance with Janssen Pharmaceutica NV
01 July
Galapagos increases share capital through warrant exercises
01 July
First patients screened for Phase 2B studies with GLPG0634
13 June
Galapagos presents GLPG0634 at EULAR poster session
17 May
Galapagos creates new warrant plan
17 May
17 May
AbbVie and Galapagos extend GLPG0634 collaboration to include Crohn's disease
13 May
Galapagos to present three posters on GLPG0634 at EULAR
30 April
NYSE Liffe lists Equity Options on Galapagos
29 April
Galapagos completes private placement by issuance of 2,696,831 new ordinary shares
25 April
24 April
Galapagos to raise capital via a private placement of new shares
23 April
Galapagos starts Phase 2A study with GLPG0974 in ulcerative colitis
22 April
Galapagos discovers novel candidate drug to treat breast cancer
16 April
Galapagos presents scope of GLPG0634 Phase 2b program
12 April
Gestion notify of 4.97% shareholding in Galapagos
08 April
Galapagos increases share capital through warrant exercises
27 March
Galapagos to start Phase 2a study with GLPG0974 in IBD patients
27 March
20 March
Galapagos to host annual R&D update on 27 March
08 March
Galapagos reports record revenues in 2012, increasing momentum in clinical pipeline
08 March
Galapagos and Roche conclude strategic alliance
06 March
Galapagos receives €7.5 million in Servier alliances
04 March
Katrine Bosley appointed to Galapagos' Board of Directors
05 February
Galapagos announces GSK2586184 JAK1 molecule progresses to Phase 2 studies
30 January
Galapagos receives €2.5 million IWT grant for IBD research
16 January
15 January
Galapagos creates Fidelta, a third Galapagos service division
15 January
Galapagos acquires Cangenix, a structure-based drug discovery company
10 January
Galapagos receives €2.7 million IWT grant for antibacterial research
09 January
Galapagos delivers candidate drug in GSK alliance and receives milestone payment
17 December
Galapagos increases share capital through warrant exercises
03 December
Galapagos opens IND for GLPG0634 in the US
26 November
Galapagos discovers novel class of antibiotics
16 November
12 November
Galapagos receives positive ruling on Patent Income Deduction
11 November
08 November
24 October
Galapagos initiates second Phase I study with GLPG0974
14 September
Galapagos increases share capital through warrant exercises
07 September
The Capital Group Companies notify of 5.85% shareholding in Galapagos
04 September
Johnson & Johnson notify of 8.8% shareholding in Galapagos
03 September
Galapagos creates new warrant plans
03 September
Galapagos subsidiary BioFocus and Ono sign a drug discovery agreement in the Field of CNS Disorders
03 August
Galapagos delivers solid half year results 2012
24 July
Galapagos delivers candidate drug in osteoarthritis alliance with Servier
18 July
Baker Brothers notify of 6.5% shareholding in Galapagos
29 June
Galapagos increases share capital through warrant exercises
22 June
Galapagos wins 2012 European Mediscience Awards
05 June
Galapagos to present GLPG0634 Phase II POC results at EULAR
30 May
23 May
Galapagos receives transparency notification
18 May
14 May
Galapagos initiates Phase IIa study with GLPG0634
27 April
18 April
05 April
Galapagos increases share capital through warrant exercises
23 March
Galapagos NV: Convocation Annual General Shareholder Meeting
21 March
06 March
Galapagos receives transparency notification
02 March
02 March
Galapagos receives €3.5 million in milestones in osteoarthritis alliance with Servier
29 February
21 February
25 January
11 November
30 May
17 December
Galapagos increases share capital through warrant exercises
03 December
Galapagos opens IND for GLPG0634 in the US
26 November
Galapagos discovers novel class of antibiotics
16 November
12 November
Galapagos receives positive ruling on Patent Income Deduction
08 November
24 October
Galapagos initiates second Phase I study with GLPG0974
14 September
Galapagos increases share capital through warrant exercises
07 September
The Capital Group Companies notify of 5.85% shareholding in Galapagos
04 September
Johnson & Johnson notify of 8.8% shareholding in Galapagos
03 September
Galapagos creates new warrant plans
03 September
Galapagos subsidiary BioFocus and Ono sign a drug discovery agreement in the Field of CNS Disorders
03 August
Galapagos delivers solid half year results 2012
24 July
Galapagos delivers candidate drug in osteoarthritis alliance with Servier
18 July
Baker Brothers notify of 6.5% shareholding in Galapagos
29 June
Galapagos increases share capital through warrant exercises
22 June
Galapagos wins 2012 European Mediscience Awards
05 June
Galapagos to present GLPG0634 Phase II POC results at EULAR
23 May
Galapagos receives transparency notification
18 May
14 May
Galapagos initiates Phase IIa study with GLPG0634
27 April
18 April
05 April
Galapagos increases share capital through warrant exercises
23 March
Galapagos NV: Convocation Annual General Shareholder Meeting
21 March
06 March
Galapagos receives transparency notification
02 March
02 March
Galapagos receives €3.5 million in milestones in osteoarthritis alliance with Servier
29 February
21 February
25 January
21 December
19 December
Galapagos increases share capital through warrant exercises
19 December
Galapagos achieves clinical Proof-of-Mechanism milestone in GSK alliance
15 December
Galapagos receives €4 million in milestones from Servier in their osteoarthritis alliance
22 November
Galapagos' GLPG0634 shows excellent efficacy and safety in rheumatoid arthritis Phase II study
10 November
07 November
04 November
Galapagos wins 2011 Scrip Award for Biotech Company of the Year
12 October
Galapagos announces second extension to services collaboration with Chiesi
03 October
Servier and Galapagos initiate strategic alliance for innovative treatments in oncology
18 August
Galapagos and Genentech extend drug discovery collaboration
05 August
Galapagos announces half year results 2011
20 July
Galapagos initiates Proof-of-Mechanism clinical study for candidate cachexia drug GLPG0492
01 July
Galapagos increases share capital through warrant exercises
28 June
Argenta signs integrated services agreement with Pulmagen Therapeutics
09 June
Galapagos initiates Phase II trial for GLPG0634
01 June
Evotec acquires compound management business from Galapagos
30 May
Ronald Brus resigns from the Galapagos Board
24 May
Galapagos to deliver four presentations at EULAR 2011
23 May
Galapagos announces approval of all EGM proposals; creates new warrant plans
13 May
12 May
Galapagos receives transparency notifications
11 May
Galapagos initiates second Proof of Mechanism clinical study in GSK alliance
20 April
Galapagos delivers validated oncology targets to Janssen
15 April
01 April
Dr Vicki Sato to be appointed to Galapagos' Board of Directors
30 March
Galapagos increases share capital through warrant exercises
14 March
Galapagos starts Phase Ib clinical study in cancer patients
04 March
Galapagos reports record revenues and increased profitability in 2010
02 March
Galapagos delivers candidate drug in GSK alliance, receives €6.7 million
08 February
Galapagos receives €4 million in milestones from Servier
07 February
Galapagos creates new warrant plan
07 February
Galapagos receives €2.7 million grant for antiviral drug discovery
04 February
Galapagos achieves €137 million revenues in 2010, outlook for continued strong 2011 performance
04 February
Galapagos and Merck & Co., Inc. agree to end strategic alliances
11 January
Galapagos receives €7.4 M milestone in arthritis alliance with GlaxoSmithKline
07 November
04 November
Galapagos wins 2011 Scrip Award for Biotech Company of the Year
12 October
Galapagos announces second extension to services collaboration with Chiesi
24 May
21 December
19 December
Galapagos increases share capital through warrant exercises
19 December
Galapagos achieves clinical Proof-of-Mechanism milestone in GSK alliance
15 December
Galapagos receives €4 million in milestones from Servier in their osteoarthritis alliance
22 November
Galapagos' GLPG0634 shows excellent efficacy and safety in rheumatoid arthritis Phase II study
10 November
03 October
Servier and Galapagos initiate strategic alliance for innovative treatments in oncology
18 August
Galapagos and Genentech extend drug discovery collaboration
05 August
Galapagos announces half year results 2011
20 July
Galapagos initiates Proof-of-Mechanism clinical study for candidate cachexia drug GLPG0492
01 July
Galapagos increases share capital through warrant exercises
28 June
Argenta signs integrated services agreement with Pulmagen Therapeutics
09 June
Galapagos initiates Phase II trial for GLPG0634
01 June
Evotec acquires compound management business from Galapagos
30 May
Ronald Brus resigns from the Galapagos Board
23 May
Galapagos announces approval of all EGM proposals; creates new warrant plans
13 May
12 May
Galapagos receives transparency notifications
11 May
Galapagos initiates second Proof of Mechanism clinical study in GSK alliance
20 April
Galapagos delivers validated oncology targets to Janssen
15 April
01 April
Dr Vicki Sato to be appointed to Galapagos' Board of Directors
30 March
Galapagos increases share capital through warrant exercises
14 March
Galapagos starts Phase Ib clinical study in cancer patients
04 March
Galapagos reports record revenues and increased profitability in 2010
02 March
Galapagos delivers candidate drug in GSK alliance, receives €6.7 million
08 February
Galapagos receives €4 million in milestones from Servier
07 February
Galapagos creates new warrant plan
07 February
Galapagos receives €2.7 million grant for antiviral drug discovery
04 February
Galapagos achieves €137 million revenues in 2010, outlook for continued strong 2011 performance
04 February
Galapagos and Merck & Co., Inc. agree to end strategic alliances
11 January
Galapagos receives €7.4 M milestone in arthritis alliance with GlaxoSmithKline
17 December
Galapagos' affiliate BioFocus extends collaboration with Amgen into 2012
16 December
Galapagos achieves milestones, broadens scope of Roche alliance
07 December
Galapagos increases share capital through warrant exercises
02 December
12 November
01 November
Galapagos receives transparency notification
28 October
Galapagos receives €3.7 million grant for cystic fibrosis program
27 October
Galapagos receives transparency notifications
22 October
Galapagos completes private placement by issuance of 2,389,347 new ordinary shares
19 October
Galapagos successfully completes placement of 2,389,347 new ordinary shares
18 October
Galapagos announces offering of new ordinary shares
18 October
Galapagos achieves milestones in two strategic alliances
14 October
Galapagos' affiliate BioFocus extends collaboration with Chiesi
12 October
Galapagos and the National Cancer Institute sign compound management agreement
05 October
Galapagos wins 2010 European Biotechnica Award
04 October
28 September
Galapagos starts Phase II clinical trial in rheumatoid arthritis patients
10 September
Argenta expands collaboration with Genentech to include BioFocus
08 September
Galapagos reaches agreement to acquire GlaxoSmithKline research centre in Zagreb, Croatia
07 September
06 August
Galapagos half year results in line with full year guidance
06 August
16 July
Galapagos and University of Bristol enter drug discovery collaboration in chronic pain
12 July
NIH extends agreement with Galapagos until end 2012
01 July
Servier and Galapagos initiate strategic alliance in osteoarthritis
29 June
Correction: transparency notification
28 June
Galapagos increases share capital through warrant exercises, receives transparency notifications
17 June
Apax shareholding in Galapagos placed with institutional investors
25 May
Galapagos achieves milestones in osteoporosis alliance
20 May
Galapagos initiates clinical studies with GLPG0492, a candidate drug for cachexia
14 May
11 May
Galapagos and Roche expand COPD alliance
29 April
28 April
Galapagos announces appointment of Ronald Brus to Board; creates new warrant plans
19 April
Galapagos to present GLPG0187 first-in-human trial results (cancelled)
08 April
Galapagos raises €2.1 million from warrant exercises, management increases shareholding
19 March
Galapagos to build cystic fibrosis drug pipeline
05 March
Galapagos reports record revenues and net profit for 2009, foresees sustained profitability
23 February
22 February
Galapagos delivers third candidate drug in GSK alliance, receives €5.7 million
19 February
18 February
Galapagos and MorphoSys expand antibody alliance
02 February
Galapagos acquires Argenta Discovery's service operations
29 January
Galapagos delivers strong 2009 performance, expects positive operating income in 2010
19 January
Galapagos candidate metastasis drug shows good safety and biomarker response
15 January
Galapagos achieves milestones in strategic alliances with Merck & Co., Inc.
12 January
Galapagos service division achieves EUR 1.6 M in payments
11 January
10 September
Argenta expands collaboration with Genentech to include BioFocus
19 April
Galapagos to present GLPG0187 first-in-human trial results (cancelled)
17 December
Galapagos' affiliate BioFocus extends collaboration with Amgen into 2012
16 December
Galapagos achieves milestones, broadens scope of Roche alliance
07 December
Galapagos increases share capital through warrant exercises
02 December
12 November
01 November
Galapagos receives transparency notification
28 October
Galapagos receives €3.7 million grant for cystic fibrosis program
27 October
Galapagos receives transparency notifications
22 October
Galapagos completes private placement by issuance of 2,389,347 new ordinary shares
19 October
Galapagos successfully completes placement of 2,389,347 new ordinary shares
18 October
Galapagos announces offering of new ordinary shares
18 October
Galapagos achieves milestones in two strategic alliances
14 October
Galapagos' affiliate BioFocus extends collaboration with Chiesi
12 October
Galapagos and the National Cancer Institute sign compound management agreement
05 October
Galapagos wins 2010 European Biotechnica Award
04 October
28 September
Galapagos starts Phase II clinical trial in rheumatoid arthritis patients
08 September
Galapagos reaches agreement to acquire GlaxoSmithKline research centre in Zagreb, Croatia
07 September
06 August
Galapagos half year results in line with full year guidance
06 August
16 July
Galapagos and University of Bristol enter drug discovery collaboration in chronic pain
12 July
NIH extends agreement with Galapagos until end 2012
01 July
Servier and Galapagos initiate strategic alliance in osteoarthritis
29 June
Correction: transparency notification
28 June
Galapagos increases share capital through warrant exercises, receives transparency notifications
17 June
Apax shareholding in Galapagos placed with institutional investors
25 May
Galapagos achieves milestones in osteoporosis alliance
20 May
Galapagos initiates clinical studies with GLPG0492, a candidate drug for cachexia
14 May
11 May
Galapagos and Roche expand COPD alliance
29 April
28 April
Galapagos announces appointment of Ronald Brus to Board; creates new warrant plans
08 April
Galapagos raises €2.1 million from warrant exercises, management increases shareholding
19 March
Galapagos to build cystic fibrosis drug pipeline
05 March
Galapagos reports record revenues and net profit for 2009, foresees sustained profitability
23 February
22 February
Galapagos delivers third candidate drug in GSK alliance, receives €5.7 million
19 February
18 February
Galapagos and MorphoSys expand antibody alliance
02 February
Galapagos acquires Argenta Discovery's service operations
29 January
Galapagos delivers strong 2009 performance, expects positive operating income in 2010
19 January
Galapagos candidate metastasis drug shows good safety and biomarker response
15 January
Galapagos achieves milestones in strategic alliances with Merck & Co., Inc.
12 January
Galapagos service division achieves EUR 1.6 M in payments